Cytokinetics, Incorporated (CYTK) vs ImmunityBio, Inc. (IBRX)
Cytokinetics, Incorporated and ImmunityBio, Inc. are both Biotechnology companies. Cytokinetics, Incorporated and ImmunityBio, Inc. are of similar size ($9.2B and $9.0B). ImmunityBio, Inc. grew revenue faster over the last twelve months: 192.9% against −21.1%. ImmunityBio, Inc. has the higher net margin (−598.6% vs −1,321.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, ImmunityBio, Inc. leads on 11 and Cytokinetics, Incorporated on 5.
Valuation
Profitability
| Metric | CYTK | IBRX | Biotechnology median |
|---|---|---|---|
| Gross margin | 87.97% | 99.34% | 65.16% |
| Operating margin | (1,046.12%) | (151.88%) | 0.00% |
| Net margin | (1,321.12%) | (598.56%) | 0.00% |
| Free cash flow margin | (858.16%) | (173.76%) | 0.00% |
| Return on equity | 329.76% | 122.85% | (57.72%) |
| Return on assets | (56.76%) | (192.58%) | (49.22%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack